Anfield Capital Management LLC Grows Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Anfield Capital Management LLC boosted its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 100.0% in the fourth quarter, HoldingsChannel reports. The fund owned 129,318 shares of the company’s stock after acquiring an additional 64,659 shares during the period. Anfield Capital Management LLC’s holdings in Zentalis Pharmaceuticals were worth $392,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Verition Fund Management LLC increased its stake in shares of Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock valued at $5,536,000 after purchasing an additional 951,500 shares in the last quarter. GSA Capital Partners LLP increased its position in Zentalis Pharmaceuticals by 138.5% during the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after buying an additional 353,384 shares in the last quarter. Primecap Management Co. CA increased its position in Zentalis Pharmaceuticals by 21.6% during the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock valued at $5,513,000 after buying an additional 265,690 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in Zentalis Pharmaceuticals by 126.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company’s stock valued at $843,000 after buying an additional 127,868 shares during the last quarter. Finally, PDT Partners LLC boosted its holdings in Zentalis Pharmaceuticals by 166.0% in the third quarter. PDT Partners LLC now owns 107,159 shares of the company’s stock worth $394,000 after acquiring an additional 66,868 shares in the last quarter.

Zentalis Pharmaceuticals Trading Up 2.5 %

Shares of ZNTL stock opened at $2.07 on Friday. Zentalis Pharmaceuticals, Inc. has a 12-month low of $1.61 and a 12-month high of $16.41. The stock has a market capitalization of $147.52 million, a P/E ratio of -0.83 and a beta of 1.82. The firm’s 50 day moving average is $2.46 and its 200 day moving average is $3.04.

Insider Activity

In other news, insider Ingmar Bruns acquired 20,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Thursday, February 6th. The stock was bought at an average price of $2.28 per share, for a total transaction of $45,600.00. Following the completion of the transaction, the insider now owns 36,629 shares in the company, valued at $83,514.12. The trade was a 120.27 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jan Skvarka bought 60,000 shares of the company’s stock in a transaction on Friday, January 31st. The stock was purchased at an average cost of $1.72 per share, for a total transaction of $103,200.00. Following the completion of the transaction, the director now directly owns 149,551 shares of the company’s stock, valued at approximately $257,227.72. The trade was a 67.00 % increase in their position. The disclosure for this purchase can be found here. Insiders own 3.60% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. HC Wainwright reduced their price target on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Wedbush reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Wells Fargo & Company dropped their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. UBS Group reduced their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, Guggenheim lowered their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $8.24.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.